

This article was downloaded by:

On: 24 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597273>

Analysis of Acetaminophen and Salicylate by Reverse Phase HPLC

William J. Ferrell^a; Gerard W. Goyette^a

^a Department of Laboratory Medicine, Children's Hospital of Michigan, Detroit, MI

To cite this Article Ferrell, William J. and Goyette, Gerard W.(1982) 'Analysis of Acetaminophen and Salicylate by Reverse Phase HPLC', *Journal of Liquid Chromatography & Related Technologies*, 5: 1, 93 – 96

To link to this Article: DOI: 10.1080/01483918208068822

URL: <http://dx.doi.org/10.1080/01483918208068822>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ANALYSIS OF ACETAMINOPHEN AND SALICYLATE BY
REVERSE PHASE HPLC

by

William J. Ferrell and Gerard W. Goyette
Children's Hospital of Michigan
Department of Laboratory Medicine
3901 Beaubien Blvd.
Detroit, MI. 48201

ABSTRACT

A method for the simultaneous measurement of acetaminophen and salicylate by reverse phase HPLC using N,N-Diethyl-m-toluamide as internal standard is described. The method, which utilizes a one step acetonitrile precipitation of serum, can be applied to as little as 25 μ L of sample. Serum is vortex-mixed with acetonitrile containing the internal standard and following centrifugation an aliquot of the supernatant is analyzed on a reverse-phase column. The eluting solvent consists of methanol/5% acetic acid (60/40,V/V) and the effluent is monitored at 248 nm.

INTRODUCTION

Both acetaminophen and salicylate are used as analgesics and antipyretics and both are generally safe. However, hepatic necrosis or fulminant hepatic failure can result from acute or severe overdose (1-3). The widespread availability and use of these drugs is a frequent cause of accidental poisoning in children. Since the time for hepatic injury to become biochemically apparent requires from 1 to 2 days (4,5) it is useful to monitor the serum levels over a period of time.

There have been time consuming gas-liquid (6) and spectrophotometric methods (7,8) described as well as several liquid chromatographic procedures (9,10,11). However, the HPLC methods either employ no internal standard, consist of a multistep extraction procedure, or do not determine both drugs simultaneously.

In this paper an HPLC method for the simultaneous determination of acetaminophen and salicylate is described, in which N,N-Diethyl-m-toluamide

is used as an internal standard. The analysis is fast and has been successfully applied to patient specimens in our pediatric service laboratory. By adjusting the detector to 0.01 absorbance units full scale (AUFs) we have been able to measure as little as 1 $\mu\text{g/ml}$ of each drug.

MATERIALS AND METHODS

Instrumentation

A constant volume liquid chromatograph from Waters (Milford, MA.) consisting of a model 6000A solvent delivery system, a U6K sample injector and a model 450 detector (interfaced with a Waters 730 Data System) set at 248 nm was used. The detector was set at 0.1 AUFs for routine analysis. The column was a prepacked μ Bondapak C18 also from Waters.

Procedure

Add 200 μL of acetonitrile, containing 80 mg/L of IS, to 50 μL of serum in a 10x75 mm glass test tube. Vortex-mix for 10 sec., followed by a 2 min. centrifugation (2500 r.p.m.). An aliquot of the supernatant (usually 20 μL) was then injected into the chromatograph. We observed no differences when 25 μL of serum and 100 μL of acetonitrile were used. When using this smaller size sample we found it more convenient to use an 0.3 ml size Mini-Vial (The Aspect Co., Inc., Ann Arbor, MI).

We quantified samples with the Waters 730 Data System using the peak height calibration mode. We found that the peak height calibration mode gave more accurate reproducibility for off scale peaks than did the peak area calibration mode.

For daily routine analysis of patient samples we use two levels of serum controls, prepared by adding acetaminophen and salicylate to drug free serum. One of these, containing 30 mg/L acetaminophen and 100 mg/L salicylate, is routinely used for the Data Module internal standard calibration; and the other, containing 20 mg/L acetaminophen and 69 mg/L salicylate, is used as the procedure control.

RESULTS AND DISCUSSION

Some typical HPLC chromatograms obtained using our procedure are shown in Figure 1. The retention times for acetaminophen, salicylate and the internal standard were 2.49, 3.84 and 5.35 min. respectively. These retention times have never varied more than 0.03 min. Figure 1A is a chromatogram of a drug free serum. Figure 1B is our control serum containing 30 mg/L acetaminophen (A) and 100 mg/L salicylate (S). Figure 1C is a patient sample calculated to contain no acetaminophen and 50 mg/L salicylate.

Recovery

Recoveries were assessed by comparing data obtained from a 50 μL aliquot of a methanol solution containing 30 mg/L acetaminophen and 100 mg/L




Figure 1. Typical chromatograms, obtained using the procedure given herein. Retention times: acetaminophen, 2.149 min.; salicylate, 3.84 min; internal standard, 5.35 min. (A) drug-free serum; (B) control serum containing 30 mg/L acetaminophen and 100mg/L salicylate; (C) patient sample, calculated to contain no acetaminophen and 50 mg/L salicylate.

salicylate to which 200 μ L of the acetonitrile-IS was added, and our serum control containing the same levels of each drug. We obtained recoveries from 96.3 to 101.2%, including the internal standard.

We also compared these recoveries to those obtained using two different extraction procedures (9,10). Using chloroform/isopropanol (9) we obtained 95 to 97% of our procedures recovery and using ethyl acetate (10) the values were less, yielding 85 to 89% of our values.

Precision

Day to day precision was assessed by assaying our control samples over a week period. The overall average of the mean coefficient of variation was 4.83% for the acetaminophen and 4.68% for salicylate. The within-run precision was evaluated by applying the method 10 times to a control serum. The mean coefficient of variation was 4.42% and 4.31% for acetaminophen and salicylate respectively.

Linearity

Acetaminophen and salicylate were added in varying concentrations to drug free serum and the samples analyzed. The results showed the present method to be linear over the ranges we tested, which were 10 mg/L to 300 mg/L for acetaminophen and 25 mg/L to 700 mg/L for salicylate.

Some typical results from a duplicate assay of various commercial serum controls are given in Table I. As can be seen all values are within the expected range. A duplicate of the control sample from our laboratory had been used to calibrate the Data Module.

The assessed accuracy, high reliability and simplicity makes the present method easily applicable to a clinical laboratory. The sample size requirements make this an especially useful method to a pediatric service laboratory.

TABLE 1
Results Of Assaying Various Controls

| Sample | Acetaminophen, mg/L | | Salicylate, mg/L | |
|------------------------|---------------------|-------|------------------|-------|
| | Expected | Found | Expected | Found |
| Sera Chem ¹ | 0 | 0 | 170-230 | 187.4 |
| | 0 | 0.69 | | 183.6 |
| Ortho I ¹ | 6-14 | 12.3 | 180-270 | 223.4 |
| | | 11.9 | | 220.6 |
| Ortho II ² | 26-38 | 38.4 | 450-550 | 536.2 |
| | | 35.5 | | 534.3 |
| Control ³ | 20 | 19.2 | 69 | 70.3 |
| | | 20.2 | | 66.3 |

¹Fisher Scientific Co., Orangebury, NJ

²Ortho Diagnostics, Raritan, NJ

³Our control made from drug free serum

REFERENCES

1. Proudfoot, A.T., and Wright, N., Br. Med. J. iii, 557(1970).
2. James, D., Roberts, S.H., Douglas, A.P., et al., Lancet ii, (579)(1975).
3. McJunkin, B., Barwick, K.W., Little, W.C., and Winfield, J.B., J. Am. Med. Assoc. 236, 1874(1976).
4. Prescott, L.F., Roscoe, P., Wright, N., and Brown, S.S., Lancet i, 519(1971).
5. Clark, R., Borirakchanyovat, V., Davidson, A.R., et al., Lancet i, 66(1973).
6. Evans, M.A., and Harbison, R.D., J. Pharm. Sci. 66, 162(1977).
7. Routh, J.I., Shane, N.A., Arredondo, E.G., and Paul, W.D., Clin. Chem. 14, 882(1968).
8. Miceli, J.N., Aravind, M.D., and Done, A.K., Pediatrics 63, 609(1979).
9. Miceli, J.N., Aravind, M.D., Cohen, S.N., and Done, A.K., Clin. Chem. 25, 1002(1979).
10. Fletterick, C.G., Grove, T.H., and Hohnadel, D.C., Clin. Chem. 25, 409(1979).
11. Altmiller, D.H., and Fowler, M.W., Clin. Chem. 23, 1138(1977).